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Summary
Objective: To investigate the immunolocalisation of b-dystroglycan (b-DG) and speciﬁc matrix metalloproteinases (MMPs)-3, -9, -13 and a dis-
integrin like and metalloproteinase thrombospondin type 1 motif 4 (ADAMTS-4) within the joint tissues of patients with osteoarthritis (OA) and
unaffected controls.
Design: Cartilage, synovium and synovial ﬂuid were obtained from the hip joints of ﬁve osteoarthritic (patients undergoing total hip replace-
ment) and ﬁve control hip joints (patients undergoing hemiarthroplasty for femoral neck fracture). The samples were analysed for b-DG protein
using Western blot technique and by immunohistochemistry for tissue distribution of b-DG, MMP-3, -9, -13, and ADAMTS-4.
Results: b-DG was detected in the smooth muscle of both normal and osteoarthritic synovial blood vessels. Importantly, b-DG was detected in
endothelium of blood vessels of OA synovium, but not in the control endothelium. In the endothelium of osteoarthritic synovial blood vessels,
b-DG co-localised with MMP-3 and -9. MMP-13 and ADAMTS-4 showed no endothelial staining, and only weak staining of the vascular
smooth muscle was found. In contrast, we did not detect b-DG protein in cartilage or synovial ﬂuid.
Conclusions: b-DG has been shown to have a role in angiogenesis, and our results demonstrate for the ﬁrst time that there are clear differ-
ences in b-DG staining between OA and control synovial blood vessels. The speciﬁc immunolocalisation of b-DG within endothelium of in-
ﬂamed OA blood vessels and its co-localisation with MMP-3 and -9, reported to have pro-angiogenic roles and believed to be involved in
b-DG cleavage, may also suggest that b-DG plays a role in angiogenesis accompanying OA.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative joint disorder in which
there is progressive loss of articular cartilage accompanied
by new bone formation and capsular ﬁbrosis. Historically, it
has always been thought of as a non-inﬂammatory disease
in order to distinguish it from other ‘inﬂammatory arthritides’
such as rheumatoid arthritis or the seronegative spondy-
loarthropathies. However, in recent years, inﬂammation
and angiogenesis are increasingly being recognised as
contributing to the symptoms and progression of OA1,2.
Many authors have shown the existence and relevance of
inﬂammatory changes in OA synovial membrane, in some
cases of similar spectrum to the inﬂammation seen in rheu-
matoid arthritis3. Inﬂammation may be both a primary and
secondary event in OA and some recent studies indicate
that histological and serological evidence of synovitis is
an early feature in OA and not restricted to patients with
end-stage disease undergoing joint replacement surgery4.
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cesses and chronic inﬂammation is almost always accom-
panied by angiogenesis, whereas angiogenesis can occur
in the absence of inﬂammation5.
A key role in the pathophysiology of OA is played by cell
to extra-cellular matrix (ECM) interactions, which are medi-
ated by cell surface integrins (transmembrane cell adhe-
sion proteins). In a physiological setting, integrins
modulate cell to ECM signalling. This is essential for reg-
ulating growth, cell differentiation and maintaining cartilage
homeostasis. In OA, abnormal integrin expression alters
cell to ECM signalling and modiﬁes chondrocyte synthesis,
with an imbalance of destructive cytokines over regulatory
factors6. Another important ECM adhesion system is the
dystroglycan (DG) complex. b-Dystroglycan (b-DG) is
a 43 kDa transmembrane protein anchoring the extracellu-
lar, ECM-interacting a-DG subunit (binding speciﬁc ECM
proteins, e.g., laminin and perlecan) to intracellular dystro-
phin7. In muscle, where its role has been characterised
most extensively, a-DG and b-DG function as part of
a large dystrophin-associated protein complex8. This
contains an array of transmembrane, cytoplasmic and
extracellular proteins vital for proper muscle function.
Dystrophin binds actin ﬁlaments of the cytoskeleton and
thus DG links the extracellular basement membrane (via181
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providing structural integrity and scaffolding for a range of
signal transduction proteins8. DG is also involved in epi-
thelial cell development, formation of basement membrane
and maintenance of tissue integrity. b-DG degradation by
MMPs disintegrates the DG complex and disrupts the
link between epithelial cells and the ECM, thus having a pro-
found effect on cell function9. MMP-evoked b-DG degrada-
tion has been described in a number of malignancies10,11.
Increased activity of speciﬁc MMPs also correlates with
both tumour invasion and metastasis, and expression of
these enzymes may also be associated with poor
outcome10,11.
Thus MMPs, the main enzymes involved in ECM break-
down, appear to connect a number of physiological and
pathological processes involving cell adhesion and signal-
ling. In the OA joint, MMPs are produced by both synovio-
cytes and chondrocytes and are sequentially activated by
an amplifying cascade, causing irreversible tissue destruc-
tion, targeting the ECM components of articular cartilage:
collagens (types II, IX, and XI) and proteoglycans (mainly
aggrecan)12. In severely damaged osteoarthritic cartilage,
chondrocyte clusters are found, which are clones of a single
chondrocyte and appear to inherit the changed pattern of
gene expression of that single abnormal chondrocyte. For
this reason, generalised expression of MMP-3, -9, -13 and
ADAMTS-4 was found in chondrocyte clones, but minimal
expression was found in normal cartilage13.
MMPs have also been shown to be involved in angiogene-
sis by helping to detach pericytes from proliferating blood
vessels14, as well as degrading the endothelial basement
membrane, releasing matrix-bound angiogenic factors and
stimulating endothelial cell migration and proliferation15. A
number of MMP inhibitors, which show anti-angiogenic activ-
ity, are already in early stages of clinical trials, primarily to
treat cancer and cancer-associated angiogenesis13. How-
ever, there is scanty data on localisation of MMP’s in blood
vessel walls; RASI-1, a novel MMP, is found to be expressed
mainly in the tunica media16. Interestingly, angiogenesis in
the synovium is associated with OA, and a recent study
showed that 31% of patients with OA showed thickened inti-
mal lining and associated lymphoid aggregates4.
b-DG has also been shown to play an angiogenic role in
cultured bovine aortic endothelial (BAE) cells whereby ex-
pression of b-DG increased BAE growth rate, reduced cell
surface area, and accelerated tube formation17. In the
same study, Hosokawa et al.17 demonstrated increased ex-
pression of b-DG within vascular endothelium of malignant
tumours (renal cell carcinoma and colon adenocarcinoma)
and benign hyperplastic tissues (gastric ulcers and nasal
polyps) compared with endothelium of normal control
tissues.
To our knowledge, there are no reports on the expression
or immunolocalisation of b-DG in human cartilage, syno-
vium or synovial ﬂuid, or its relationship with MMPs. We
investigated here the immunolocalisation of b-DG and
MMP-3, -9, -13 and ADAMTS-4 within these tissues in
both osteoarthritic and control hip joints.
Materials and methods
TISSUE SAMPLES
Patients were selected for the study if they fulﬁlled three
criteria: ﬁrstly, symptoms of severe OA, radiological evi-
dence of OA, and intra-operative macroscopic evidence of
grades 3 and 4 OA (Kellgren and Lawrence Scale18).Control patients were selected for inclusion in the study if
they had suffered fracture neck of femur requiring hemiar-
throplasty, had no pre-existing history of OA symptoms,
no radiographic evidence of OA and only grade 1 or less
macroscopic evidence of OA. Cartilage, synovium and sy-
novial ﬂuid were obtained from the hip joints of ﬁve osteoar-
thritic (patients undergoing total hip replacement for primary
OA) and ﬁve control hip joints (patients undergoing hemiar-
throplasty for femoral neck fracture). Prior to opening the
joint capsule, needle aspiration was performed for synovial
ﬂuid sampling. On opening the joint capsule, the innermost
layer of the synovium lined capsule (in contact with and
nearest the joint cavity) was harvested and processed in
three different ways: (1) sample was ﬂash frozen in liquid ni-
trogen for protein extraction and Western blot analysis; (2)
sample was ﬂash frozen in isopentane chilled at 196(C
(liquid nitrogen) for frozen section histology; (3) sample
placed in 8% formalin for later processing and wax embed-
ding. The samples were used in accordance with the insti-
tutional guidelines and the ethical permission granted by
the South West Local Research Ethics Committee.
PRIMARY ANTIBODIES
Mouse monoclonal anti-b-DG NCL-b-DG (Novocastra,
UK) recognising 15 amino acids at the extreme C-terminus
of human DG.
Rabbit anti-human MMP-13 (Serotec) recognising the
hinge region of MMP-13.
Rabbit anti-human ADAMTS-4 (Serotec), raised against
the C-terminal.
Mouse monoclonal anti-human MMP-9 (Chemicon Inter-
national, CA) is directed against the carboxy terminal do-
main of human MMP-9, residues 626e644.
Mouse monoclonal anti-human MMP-3 (Chemicon Inter-
national, CA) speciﬁcally reacts with precursor and active
forms of human MMP-3.
Mouse anti-CD31 monoclonal antibody (Chemicon Inter-
national, CA) speciﬁcally stains vascular endothelial cells
(VEC).
IMMUNOLOCALISATION
Cryosections (10 mm) were cut, mounted on Superfrost
Plusglass slidesand ﬁxedwith 4% (w/v) paraformaldehyde
in phosphate buffered saline (PBS) for 15 min on ice. Formal-
dehyde ﬁxed, parafﬁn-embedded sections (7 mm) were cut
and mounted on Superfrost Plus glass slides. For the par-
afﬁn sections to be stained with b-DG antibody, antigen re-
trieval was carried out in 0.01 M citrate buffer for 5 min in
a microwave at 900 W. The sections incubated with MMP-
3, -9, -13 and ADAMTS-4 antibodies did not necessitate an-
tigen retrieval. Once the parafﬁn-embedded sections had
been de-waxed and re-hydrated through xylene and ethanol
to water, the sections were then ﬁxed with 4% (w/v) parafor-
maldehyde in PBS for 15 min on ice. One hundredmicrolitres
of synovial ﬂuid was spun at 1500 rpm for 5 min onto a super-
frost plus slide. All sections were then pre-incubated for
30 min in PBS containing 10% (v/v) normal horse serum,
and further treated with Vector Blocking Kit to block endoge-
nous biotin activity. After blocking, the sections were incu-
bated for 2 h at room temperature in PBS containing 10%
(v/v) normal horse serum and mouse monoclonal b-DG anti-
body NCL-b-DG at a 1:100 dilution for frozen sections and
1:25 dilution for the parafﬁn sections. Following incubation
with the primary antibody, the sections were washed,
1183Osteoarthritis and Cartilage Vol. 14, No. 11incubated for 30 min with horse anti-mouse biotinylated sec-
ondary antibody (1:200, Vector Laboratories, UK) diluted in
PBS with 2% normal horse serum and the signal was visual-
ised with Vectastain ABC reagent and Vector VIP substrate
kit. The sections were counter-stained with methyl green
(Vector Laboratories, UK), dehydrated and mounted in
DPX. The above steps were repeated with the MMP anti-
bodies: MMP-3 and -9 primary antibodies at 1:200 and
1:500 dilutions, respectively, with horse anti-mouse biotiny-
lated secondary antibody at 1:200 dilution; MMP-13 and
ADAMTS-4 primary antibodies at 1:100 dilution, with goat
anti-rabbit biotinylated secondary antibody at 1:200 dilution.
For endothelial cell staining (to enable calculation of blood
vessel density) mouse anti-CD31 monoclonal primary anti-
body (at 1:200 dilution) was used, followed by goat anti-
mouse biotinylated secondary antibody (at 1:200 dilution).
In all experiments, speciﬁc tissue sections where primary an-
tibodywas omitted acted as negative controls (Figs. 5 and 6).
Staining H-score19 was based on staining area and inten-
sity within the target tissue.
Staining area was scored as follows:
1 e 0e25% surface area stained of target tissue
2 e 26e50% surface area stained of target tissue
3 e 51e75% surface area stained of target tissue
4 e 76e100% surface area stained of target tissue
Staining intensity was scored as follows:
0 e none
1 e weak
2 e moderate
3 e strong
Observers were blinded with respect to the groups and
each sample was anonymised and allocated an alphanu-
merical code, with no indication as to whether the sample
belonged to the OA group or control.
The staining intensity score was multiplied by the median
% staining area score for each category in order to derive
an overall staining score between 0 and 264. A score of
>120 was considered positive. A score <120 was consid-
ered negative. Blood vessel count was assessed using
the method previously described by Weidner et al.20.
WESTERN BLOTTING
Protein extraction
Tissues (osteoarthritic and control human cartilage and
synovium) were homogenised in ice-cold buffer containing
10 mM 2-[4-(2-hydroxyethyl)-1-piperazine]ethane sulfonic
acid (pH 7.5), 0.5% Triton X-100, 5 mM, ethylene-bis-
(oxyethylenenitrilo)-tetra-acetic acid (EGTA) 5 mM ethylene
(oxyethylene nitrilo)tetraacetic acid, 2 mM sodium chloride
and protease inhibitors (Complete, Roche) using polytron.
After incubation on ice for 25 min on a shaking platform, the
samples were centrifuged at 200 g for 5 min at 4(C and the
supernatants were centrifuged again at 16,000 g for 25 min
at 4(C. For immunoblotting, the protein pellets were solubi-
lised for 4 min at 100(C in solubilisation buffer (50 mM Tri-
seHCl; pH 7.5, 2% (w/v) sodium dodecyl sulphate (SDS),
and 1% (w/v) dithiothreitol).
SDS-polyacrylamide gel electrophoresis
Solubilised proteins (30e50 mg) were mixed with
Laemlli sample buffer (Bio RAD, UK) and 0.05%mercaptoethanol was heated to 95(C for 4 min, sepa-
rated on 6% SDS-polyacrylamide gels and electroblotted
onto Hybond ECL (enhanced chemiluminescence) mem-
branes (Amersham Pharmacia Biotech, Bucks, UK). The
blots were incubated overnight with a blocking solution
containing 5% non-fat milk powder in PBST (PBS/0.05%
Tween 20) at 4(C and then incubated with NCL-b-DG at
1:50 dilution for 2 h at room temperature. Following three
washes with PBST, membranes were incubated with
horseradish peroxidase-conjugated secondary anti-mouse
IgG (1:10,000, Amersham Pharmacia, Biotech UK) at room
temperature for 30 min and the signal was then visualised
on ﬁlms using the ECL plus kit (Amersham Pharmacia Bio-
tech, UK). As a negative control, the primary antibody was
omitted from the incubation mixture and the rest of the pro-
tocol was performed as described above. Human skeletal
muscle sample was used as a positive control.
Results
IMMUNOHISTOCHEMISTRY
Initially, we analysed the localisation of b-DG in normal
and osteoarthritic human cartilage, synovium and synovial
ﬂuid. b-DG was not detected in either normal or osteoar-
thritic cartilage or synovial ﬂuid (results not shown).
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Fig. 1. b-DG immunolocalisation in synovium. Frozen section show-
ing b-DG staining within small diameter blood vessels in control
synovium (arrows) (A). Similar frozen section showing staining
within signiﬁcantly larger diameter and more abundant blood ves-
sels within OA synovium (arrows) (B). Parafﬁn section of control
synovium showing b-DG staining in smooth muscle (sm) only (C).
Parafﬁn section of OA synovium showing strong b-DG staining in
endothelial cells (e) as well as in smooth muscle (sm) (D). Magniﬁ-
cations: (A and B) 10; (C and D) 40.
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nule blood vessel walls, but not in synoviocytes. Figure 1(A)
demonstrates a fresh frozen section of normal (control)
synovium. The synoviocytes are seen as background green
staining (methyl green counterstained) and the small blood
vessels (mainly venules and arterioles) are readily seen to
stain positively (purple) for b-DG. Figure 1(B) demonstrates
clear b-DG staining within larger diameter arterioles and ve-
nules in a fresh frozen section of osteoarthritic synovium.
Once again, the synoviocytes do not stain positively for
b-DG. Negative controls are shown in Fig. 5.
The blood vessel density count was performed using the
CD31 speciﬁc vascular endothelium antibody. The blood
vessels appeared to be of a larger diameter with greater
density in number in inﬂamed OA synovium compared
with the control synovium. The mean blood vessel density
increased from 5.2 (range 3e8) vessels per 10 ﬁeld of
view in normal synovium to 22.9 (range 15e32) vessels
per 10 ﬁeld of view in osteoarthritic synovium (Table I).
This represented an increase of 4.4 fold (P< 0.0001).
Figure 1(C) shows a cross-section of a typical arteriole in
a control synovium parafﬁn embedded section. It shows
clear positive staining (purple) of the smooth muscle layer
of the vessel wall (sm), but negative staining (green) of
the endothelial cells (e) lining the inside of the blood vessel.
Figure 1(D) again shows a similar arteriole this time within
a sample of OA synovium. This blood vessel exhibits
a strong positive staining of the endothelial cells (e) in addi-
tion to positive staining of the smooth muscle (sm).
Table II summarises the immunolocalisation data for
b-DG and MMP staining in OA and control synovium as rep-
resented in Fig. 2. The full immunolocalisation data as re-
corded using H-score are represented in Table III. As
seen in Fig. 2(AeH), there was a clear difference in staining
patterns of cross-sections of blood vessels within either
inﬂamed or control (normal) synovium with speciﬁc MMP
antibodies: MMP-3, -9, -13 and ADAMTS-4. There was no
staining of MMP-3, -9 or -13 within any part of the
control synovium blood vessel walls [Fig. 2(A, C and E)].
ADAMTS-4 staining was noticeable within the endothelium
(arrow) of the blood vessel wall, but no staining was found
within the smooth muscle or tunica adventitia [Fig. 2(G)]. In
contrast, within OA synovium there was staining of MMP-3
in both endothelium and tunica adventitia of blood vessels
[Fig. 2(B)]. MMP-9 staining appeared within the endothe-
lium only [Fig. 2(D)]. The MMP-13 and ADAMTS-4 staining
was clearly detected in the smooth muscle layer of the OA
Table I
Blood vessel count
(10)
Field of
view (f.o.v.)
OA group e number
of blood vessels
per f.o.v.
Control group e number
of blood vessels
per f.o.v.
Patient 1 15 4
Patient 1 25 3
Patient 2 22 3
Patient 2 32 7
Patient 3 31 6
Patient 3 19 3
Patient 4 20 6
Patient 4 30 8
Patient 5 16 5
Patient 5 19 7
Mean 22.9 5.2
Factor increase 4.4blood vessels, but endothelium and tunica adventitia re-
mained negative [Fig. 2(F and H)].
When comparing the blood vessel staining characteris-
tics, it can be seen that MMP-3 [Fig. 2(B)] and MMP-9
[Fig. 2(D)] appear to co-localise with b-DG [Fig. 1(D)] in
blood vessel endothelium of OA synovium. This may indi-
cate that MMP-3, MMP-9 and b-DG are linked in the pro-
cess of angiogenesis. MMP-3 staining was also increased
in the tunica adventitia of OA synovium [Fig. 2(B)]. MMP-13
[Fig. 2(F)] and ADAMTS-4 [Fig. 2(H)] staining was
increased in the smooth muscle of blood vessels of OA
synovium. ADAMTS-4 staining was increased in control
synovium endothelium [Fig. 2(G)] compared with OA syno-
vium. Figure 6 shows the MMP immunohistochemistry neg-
ative control slides.
WESTERN BLOT ANALYSIS
We extended the immunolocalisation ﬁndings of b-DG, by
analysing protein extracts from human cartilage (OA and
control), OA synovium, and synovial ﬂuid from the OA joint
space. In the skeletal muscle sample used as positive con-
trol, we found one band of the expected size (43 kDa). In
the cartilage and synovial ﬂuid samples, no signal was de-
tected, while in both OA and in control synovium samples,
an expected size band of 43 kDa was found (Figs. 3 and 4).
This conﬁrmed that the results of the immunohistochemistry
showing b-DG strongly staining the synovium blood vessels
was speciﬁc. In addition, a weaker (w30 kDa) band was de-
tected in both OA and control synovium samples. There
was no signiﬁcant difference in the intensity of this band
(corresponding to the known b-DG breakdown product) be-
tween OA and control synovium samples.
Discussion
The absence of staining of b-DG in either normal or OA car-
tilage or synovial ﬂuid would suggest that, unlike in some epi-
thelia and skeletal muscle, this protein does not play
a signiﬁcant role in the maintenance of cartilage celleECM in-
teractions and is not upregulated in response toOApathology.
b-DG has been detected in vascular smooth muscle of
normal and OA synovium. Its role in maintaining the
Table II
Summary of immunohistochemical staining of synovium blood
vessels
A) Summary immunohistochemical staining of
control synovium blood vessels
Normal synovium Endothelium Smooth muscle Adventitia
b-DG  þ 
MMP-3   
MMP-9   
MMP-13   
ADAMTS-4 þ  
B) Summary immunohistochemical staining of
OA synovium blood vessels
OA synovium Endothelium Smooth muscle Adventitia
b-DG þ þ 
MMP-3 þ  þ
MMP-9 þ  
MMP-13  þ 
ADAMTS-4  þ 
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have the same role in vascular smooth muscle. We noted
that the neovascularisation in OA synovium amounted to
a 4.4 fold increase in blood vessel density as compared
to normal synovium. This is higher than the results pub-
lished in the study by Giatromanolaki et al.21 who found
an increase in the blood vessel density in the OA syno-
vium to be of about 1.7 fold. Our results may show
this greater increase in angiogenesis compared with the
Giatromanolaki study due to the fact that we speciﬁcally
selected patients with severe OA (grade 3 or 4), which
may have contributed to and/or been contributed to by
severe inﬂammation and angiogenesis within the joint
capsule.
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Fig. 2. MMP staining of blood vessels. e¼ vascular endothelium,
sm¼ smooth muscle of blood vessel, a¼ tunica adventitia. There
is no staining of control blood vessels with MMP-3 (A), MMP-9
(C), and MMP-13 (E). ADAMTS-4 is expressed in endothelium of
control synovium (G). MMP-3 is expressed in endothelium and ad-
ventitia of OA synovium (B). MMP-9 is expressed in endothelium of
OA synovium (arrows) (D). MMP-13 is expressed in smooth muscle
of OA synovium (arrows) (F). ADAMTS-4 is expressed in smooth
muscle of OA synovium (arrow) (H). Magniﬁcation: (AeH)¼ 40.All of the arterioles and venules within both OA and control
synovium exhibited DG staining within the smooth muscle
layer. However, our study showed marked staining of b-DG
in the vascular endothelium in OA synovium samples, in con-
trast to complete absence in endothelium of normal syno-
vium. The increased staining of b-DG in OA synovium
vascular endothelium may be due to upregulation of b-DG
in its role as a pro-angiogenic molecule. VEC undergo signif-
icantmorphological and functional changesduringangiogen-
esis. To form a new blood vessel, the cells must degrade the
basement membrane, detach from the original site, explore
their way by digesting the matrix, proliferate and ﬁnally
change their shape to form a cylindrical tube. The behaviour
of every VEC is inﬂuenced by the ECM. The laminin family of
proteins is one of the most important constituents of the vas-
cular basementmembrane, and laminin binds to theDGcom-
plex.b-DGhasbeenshown to play anactive role in the in vitro
angiogenesis of BAE cells; Hosokawa et al.17 demonstrated
that changes in b-DGexpression level affected the behaviour
and phenotype of VEC in adhesion, migration, proliferation
and tube formation assays. Overexpression of the cytoplas-
mic domain of b-DG protein in BAE cells produced increased
Table III
Staining H-scores for synovium blood vessels
A) Staining H-scores for OA synovium blood vessels
OA group b-
DG
MMP-
3
MMP-
9
MMP-
13
ADAMTS-
4
Patient 1 Endothelium 189 264 264 0 12
Smooth muscle 264 12 0 126 126
Adventitia 76 189 38 38 38
Patient 2 Endothelium 264 264 264 0 12
Smooth muscle 264 38 12 126 189
Adventitia 0 176 38 63 38
Patient 3 Endothelium 189 264 126 0 0
Smooth muscle 189 0 38 264 176
Adventitia 0 189 76 0 38
Patient 4 Endothelium 189 264 264 38 24
Smooth muscle 264 88 12 176 176
Adventitia 38 189 63 63 38
Patient 5 Endothelium 126 264 189 38 0
Smooth muscle 264 12 0 176 126
Adventitia 0 264 88 88 0
B) Staining H-scores for Control synovium blood vessels
Control
group
b-
DG
MMP-
3
MMP-
9
MMP-
13
ADAMTS-
4
Patient 1 Endothelium 0 88 0 0 176
Smooth muscle 264 0 0 88 0
Adventitia 88 88 12 0 12
Patient 2 Endothelium 0 76 0 38 126
Smooth muscle 264 12 63 63 63
Adventitia 63 88 12 0 12
Patient 3 Endothelium 63 88 38 12 88
Smooth muscle 189 24 0 12 0
Adventitia 189 88 12 63 38
Patient 4 Endothelium 0 76 88 0 264
Smooth muscle 264 12 88 88 88
Adventitia 189 126 12 63 12
Patient 5 Endothelium 88 0 0 63 176
Smooth muscle 264 12 0 88 12
Adventitia 108 88 0 0 12
1186 S. Wimsey et al.: Immunolocalisation of b-dystroglycangrowth rates and tube formation. b-DG is also overexpressed
inVECsofmalignant tumours (renal cell carcinomaandcolon
adenocarcinoma) and benign hyperplastic tissues (gastric ul-
cers and nasal polyps) as comparedwith VEC of their normal
control counterparts. These immunohistochemical results
suggest close correlation between the expression of DG in
VEC and angiogenesis17. Durbeej et al.22 suggested that
the positive signals of DG staining in some blood vessels
emanated from smooth muscle cells that expressed DG at
a high level. However, the BAE adhesion was inhibited by
a set of glycosaminoglycans (heparin, dextransulphate and
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Fig. 3. Western blot analysis of b-DG expression in joint tissues.
One band of expected size (43 kDa) (black arrow) was detected
in human muscle control and OA synovium. This band and a sec-
ond, weaker band of w30 kDa (pointed arrow) were detected in
the OA synovium. Neither cartilage nor synovial ﬂuid was positive
for DG expression.
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Fig. 4. Western blot analysis of b-DG expression in OA and control
synovium. One band of expected size (43 kDa) was detected in
both OA synovium and control synovium. A second, weaker band
of w30 kDa was detected in both OA synovium and control syno-
vium. Similar intensity bands with actin (42 kDa) for all three sam-
ples conﬁrm similar protein loadings.fucoidan) that were shown to disrupt DG-laminin-dependent
cell adhesion in several other cell types23. Serial analysis of
gene expression revealed the presence of a considerable
number of genes whose expression was upregulated in
VEC in tumours, several of the upregulated genes being
those of ECM proteins24. Although the above work by Hoso-
kawa et al. has focused on angiogenesis in hyperplastic and
neoplastic tissues, we hypothesize that the same process of
b-DG upregulationmay occur in angiogenic and inﬂamedOA
synovium, as we have observed the same differences in
staining characteristics in blood vessel endothelium. This
leads us to believe therefore that at a molecular level, these
important, butasyetunexplained interactions,mayplayacru-
cial role in the pathogenesis of OA. Furthermore, DG expres-
sion may be used as a molecular target to speciﬁcally inhibit
blood vessel formation in tumours or hyperplastic tissues or
to deliver drugs to tumours via speciﬁc endothelial cells ex-
pressing DG17.
MMPs, the main enzymes involved in ECM breakdown,
are known to be expressed and activated in OA, causing ir-
reversible tissue destruction by targeting the ECM compo-
nents of articular cartilage12,13. However, MMPs have also
been shown to be involved in angiogenesis14,15 and for
this reason we analysed staining patterns of speciﬁc
MMPs here. This is particularly interesting, as we have
also shown co-localisation of speciﬁc MMPs and b-DG in
endothelial cells and Yamada et al.9 demonstrated proteo-
lytic processing of b-DG via MMPs in certain tissues.
Such processing disintegrates the DG complex and dis-
rupts the link between the cells and the ECM.
Increased staining of MMP-3 and -9 in the endothelium,
increased staining of MMP-13 and ADAMTS-4 in the
smooth muscle and increased staining of MMP-3 in the ad-
ventitia of OA synovium may indicate varied roles for each
of these MMPs. For instance, MMP-9 within membrane ves-
icles in endothelial cells is released when angiogenically
stimulated by vascular endothelial growth factor (VEGF)25.
The co-localisation of MMP-3 and -9 with b-DG in the endo-
thelium of OA synovium may indicate interaction between
Fig. 5. b-DG immunolocalisation in synovium including negative
controls. Frozen sections 10 magniﬁcation. (A) and (B) are con-
secutive slides, as are (C) and (D). (A) OA synovium. (B) OA syno-
vium negative control (primary antibody omitted). (C) Control
synovium. (D) Control synovium negative control (primary antibody
omitted).
1187Osteoarthritis and Cartilage Vol. 14, No. 11the enzymes and b-DG in the process of angiogenesis. In-
terestingly, the Western blot results indicated that b-DG
degradation in OA synovium was not increased signiﬁcantly
in comparison to control samples. This suggests that in-
creased expression of these speciﬁc MMPs cannot be auto-
matically linked with increased DG degradation in OA, as it
has been the case in other tissues26.
Lack of staining of ADAMTS-4 in either the tunica adven-
titia or endothelium of osteoarthritic synovium indicates that
it is not pro-angiogenic, and in fact its staining is greatest in
the normal endothelium of the control synovium. This is in
keeping with the ﬁndings of Overall et al.27, who showed
the ADAMTS family to have anti-angiogenic activity.
Previous research has demonstrated that MMP synthesis
occurs in both OA synoviocytes3,28e30 and OA chondro-
cytes13,31. Here we demonstrate increased staining of
Fig. 6. MMP immunolocalisation in synovium e negative controls
(primary antibody omitted). Control synovium (A, C, E, G) and OA
synovium (B, D, F, H).speciﬁc MMPs in osteoarthritic synovium blood vessels
compared with control synovium. Therefore, if this produc-
tion of MMPs can be down-regulated or manipulated, this
may provide yet another avenue for medical treatment of
OA. Similarly, as we have identiﬁed increased b-DG
staining within OA synovium blood vessel endothelium, fur-
ther studies to understand the exact role of this protein in
angiogenesis are warranted as it may provide yet another
therapeutic target in OA and related diseases, where inhibi-
tion of angiogenesis may be beneﬁcial.
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